SMI (Starch Medical Inc.) is a San Jose, CA based medical device company engaged in the design, manufacture and sale of innovative, absorbable surgical hemostats synthesized from Absorbable Modified Polymers (AMP™), a proprietary, patent pending technology. SMI has organized a global distribution network for the marketing and sales of PerClot™ Polysaccharide Hemostatic System (PHS), which launched in the 4th Quarter, 2008.  StarFoam™ and SealFoam™ absorbable polysaccharide hemostats were awarded a CE mark in December, 2008 and will be introduced in 2009.

Absorbable Modified Polymer (AMP™) technology is a proprietary engineering process that modifies plant starch into ultra-hydrophilic, adhesive forming hemostatic polymers. AMP™ materials are biocompatible, absorbable polysaccharides containing no animal or human components. Utilizing this purified plant source material is critical to minimizing the risks of infection and bleeding-related complications during surgery.  At SMI, patient safety is the ultimate specification.

AMP™ particles have a molecular structure that rapidly absorbs water from blood, creating a high concentration of platelets, red blood cells and coagulation proteins at bleeding site, which accelerates the physiologic clotting cascade.   The AMP™ on blood interaction rapidly produces a gelled matrix that adheres to and forms a mechanical barrier with the bleeding tissue.  AMP™ particles are readily dissolved by saline irrigation and are totally absorbed within several days.

Safe: bioinert, plant-based source; rapid absorption within 2-3 days
Effective: ultra-hydrophillic, hemostatic control
Easy: off the shelf deployment with no prep
Diversifed: technology platforms in powder, foam, film
Customized: for open and minimally invasive applications